文献速递类风湿关节炎

阿托伐他汀用于类风湿关节炎心血管事件一级预防的多中心随机安慰剂对照试验

A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2019-07-22

本研究为多中心随机双盲安慰剂对照试验,纳入3002例无临床动脉粥样硬化、糖尿病或肌病的RA患者,随机接受阿托伐他汀40mg每日或安慰剂,中位随访2.51年。主要终点事件率低于预期(0.70%/年),研究提前终止;阿托伐他汀组主要终点发生24例(1.6%),安慰剂组36例(2.4%),HR 0.66(95%CI 0.39,1.11;P=0.115),未达统计学显著。阿托伐他汀安全,显著降低LDL胆固醇和CRP。

要点

  • 阿托伐他汀40mg/日使RA患者LDL胆固醇较安慰剂平均降低0.77±0.04 mmol/L(P<0.0001)。
  • 主要心血管终点HR 0.66(95%CI 0.39,1.11;P=0.115),未达统计学显著。
  • 阿托伐他汀组与安慰剂组不良事件发生率相似(19.8% vs 19.5%)。

核心结论

  • 阿托伐他汀40mg每日在RA患者中安全,且较安慰剂显著降低LDL胆固醇水平。
  • 34%的心血管事件风险降低与胆固醇治疗试验者协作组荟萃分析在其他人群中的他汀效应一致。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验,设计检测基于估计年事件率1.6%的32%心血管事件风险降低,80%把握度,P<0.05。
  • 纳入年龄>50岁或病程>10年、无临床动脉粥样硬化、糖尿病或肌病的RA患者,随机接受阿托伐他汀40mg每日或匹配安慰剂。
  • 共3002例患者(平均年龄61岁;74%女性),中位随访2.51年(IQR 1.90,3.49年),共7827患者年。

主要发现

  • 研究因事件率低于预期(0.70%/年)提前终止。
  • 阿托伐他汀组1504例中24例(1.6%)发生主要终点,安慰剂组1498例中36例(2.4%)发生主要终点(HR 0.66 [95%CI 0.39,1.11];P=0.115;校正HR 0.60 [95%CI 0.32,1.15];P=0.127)。
  • 试验结束时,阿托伐他汀组LDL胆固醇较安慰剂组平均低0.77±0.04 mmol/L(P<0.0001)。
  • 阿托伐他汀组C反应蛋白中位数2.59 mg/L(IQR 0.94,6.08)显著低于安慰剂组3.60 mg/L(IQR 1.47,7.49)(P<0.0001)。
  • LDL胆固醇每降低1 mmol/L的心血管事件风险降低为42%(95%CI -14%,70%)。

关键数值与推荐

  • 主要终点为心血管死亡、心肌梗死、卒中、短暂性脑缺血发作或任何动脉血运重建的复合终点。
  • 阿托伐他汀组不良事件298例(19.8%),安慰剂组292例(19.5%),发生率相似。

临床怎么用

  • 对于年龄>50岁或病程>10年且无临床动脉粥样硬化、糖尿病或肌病的RA患者,阿托伐他汀40mg每日可安全用于显著降低LDL胆固醇和CRP。
  • 尽管主要终点未达统计学显著,但34%的心血管事件风险降低与在其他人群中观察到的他汀效应一致,支持在RA患者中考虑他汀治疗。

局限性

  • 研究因事件率低于预期而提前终止,可能把握度不足。
  • 主要终点结果未达统计学显著(P=0.115)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Rheumatoid arthritis (RA) is associated with increased cardiovascular event (CVE) risk. The impact of statins in RA is not established. We assessed whether atorvastatin is superior to placebo for the primary prevention of CVEs in RA patients. METHODS: A randomized, double-blind, placebo-controlled trial was designed to detect a 32% CVE risk reduction based on an estimated 1.6% per annum event rate with 80% power at P < 0.05. RA patients age >50 years or with a disease duration of >10 years who did not have clinical atherosclerosis, diabetes, or myopathy received atorvastatin 40 mg daily or matching placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, transient ischemic attack, or any arterial revascularization. Secondary and tertiary end points included plasma lipids and safety. RESULTS: A total of 3,002 patients (mean age 61 years; 74% female) were followed up for a median of 2.51 years (interquartile range [IQR] 1.90, 3.49 years) (7,827 patient-years). The study was terminated early due to a lower than expected event rate (0.70% per annum). Of the 1,504 patients receiving atorvastatin, 24 (1.6%) experienced a primary end point, compared with 36 (2.4%) of the 1,498 receiving placebo (hazard ratio [HR] 0.66 [95% confidence interval (95% CI) 0.39, 1.11]; P = 0.115 and adjusted HR 0.60 [95% CI 0.32, 1.15]; P = 0.127). At trial end, patients receiving atorvastatin had a mean ± SD low-density lipoprotein (LDL) cholesterol level 0.77 ± 0.04 mmoles/liter lower than those receiving placebo (P < 0.0001). C-reactive protein level was also significantly lower in the atorvastatin group than the placebo group (median 2.59 mg/liter [IQR 0.94, 6.08] versus 3.60 mg/liter [IQR 1.47, 7.49]; P < 0.0001). CVE risk reduction per mmole/liter reduction in LDL cholesterol was 42% (95% CI -14%, 70%). The rates of adverse events in the atorvastatin group (n = 298 [19.8%]) and placebo group (n = 292 [19.5%]) were similar. CONCLUSION: Atorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholesterol level than placebo in patients with RA. The 34% CVE risk reduction is consistent with the Cholesterol Treatment Trialists' Collaboration meta-analysis of statin effects in other populations.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Kitas GD, Nightingale P, Armitage J, et al. A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2019. PMID: 30983166. doi:10.1002/art.40892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。